- Home
- SWVL vs XCUR Comparison
SWVL vs XCUR Comparison
Compare SWVL & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWVL
- XCUR
- Stock Information
- Founded
- SWVL 2017
- XCUR 2011
- Country
- SWVL United Arab Emirates
- XCUR United States
- Employees
- SWVL N/A
- XCUR N/A
- Industry
- SWVL Business Services
- XCUR Biotechnology: Pharmaceutical Preparations
- Sector
- SWVL Consumer Discretionary
- XCUR Health Care
- Exchange
- SWVL Nasdaq
- XCUR Nasdaq
- Market Cap
- SWVL 37.6M
- XCUR 32.4M
- IPO Year
- SWVL N/A
- XCUR N/A
- Fundamental
- Price
- SWVL $3.47
- XCUR $4.07
- Analyst Decision
- SWVL
- XCUR
- Analyst Count
- SWVL 0
- XCUR 0
- Target Price
- SWVL N/A
- XCUR N/A
- AVG Volume (30 Days)
- SWVL 17.2K
- XCUR 27.7K
- Earning Date
- SWVL 09-08-2025
- XCUR 11-13-2025
- Dividend Yield
- SWVL N/A
- XCUR N/A
- EPS Growth
- SWVL N/A
- XCUR N/A
- EPS
- SWVL N/A
- XCUR N/A
- Revenue
- SWVL $19,329,423.00
- XCUR N/A
- Revenue This Year
- SWVL N/A
- XCUR N/A
- Revenue Next Year
- SWVL N/A
- XCUR N/A
- P/E Ratio
- SWVL N/A
- XCUR N/A
- Revenue Growth
- SWVL N/A
- XCUR N/A
- 52 Week Low
- SWVL $2.40
- XCUR $1.91
- 52 Week High
- SWVL $7.50
- XCUR $36.00
- Technical
- Relative Strength Index (RSI)
- SWVL 41.69
- XCUR 28.07
- Support Level
- SWVL $3.33
- XCUR $3.10
- Resistance Level
- SWVL $4.01
- XCUR $7.06
- Average True Range (ATR)
- SWVL 0.33
- XCUR 0.38
- MACD
- SWVL 0.02
- XCUR -0.11
- Stochastic Oscillator
- SWVL 34.94
- XCUR 31.37
About SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.